The abstract for tomorrow's presentation does not indicate that we are going to hear about the eGFR data in the CKD patient population. While this could be due to lack of effect - I tend to doubt that this would be the reason for omitting this important piece of information. It could just as well be related to RVX trying to patent an effect we have not yet heard about.

This is just to say that no news is not necessarily bad news.

BR.

BKC